

Female Sexual Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/FCA5582DC3C2EN.html>

Date: December 2022

Pages: 69

Price: US\$ 2,000.00 (Single User License)

ID: FCA5582DC3C2EN

Abstracts

Female Sexual Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction - Drugs In Development, 2022, provides an overview of the Female Sexual Dysfunction (Women's Health) pipeline landscape.

Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Sexual Dysfunction - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Sexual Dysfunction (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase 0, Preclinical, Discovery and Unknown stages are 3, 6, 1, 7, 2 and 1 respectively.

Female Sexual Dysfunction (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction (Women's Health).

The pipeline guide reviews pipeline therapeutics for Female Sexual Dysfunction (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Female Sexual Dysfunction (Women's Health) therapeutics and enlists all their major and minor

projects.

The pipeline guide evaluates Female Sexual Dysfunction (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction (Women's Health)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Female Sexual Dysfunction (Women's Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Female Sexual Dysfunction (Women's Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Female Sexual Dysfunction - Overview

Female Sexual Dysfunction - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Female Sexual Dysfunction - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Female Sexual Dysfunction - Companies Involved in Therapeutics Development

Autotelic Bio Inc

Callitas Therapeutics Inc

Can-Fite BioPharma Ltd

Dare Bioscience Inc

Endoceutics Inc

Freya Pharma Solutions BV

Jupiter Wellness Inc

Kuhnle Pharmaceutical Co Ltd

Lennham Pharmaceuticals Inc

Palatin Technologies Inc

S1 Biopharma Inc

TherapeuticsMD Inc

Thomas Advanced Medical LLC

Viramal Ltd

Female Sexual Dysfunction - Drug Profiles

(buspirone hydrochloride + testosterone) - Drug Profile

Product Description

Mechanism Of Action

(sildenafil citrate + testosterone) - Drug Profile

Product Description

Mechanism Of Action

apomorphine - Drug Profile

Product Description

Mechanism Of Action

bremelanotide acetate - Drug Profile

Product Description

Mechanism Of Action

estradiol - Drug Profile

Product Description

Mechanism Of Action

JW-500 - Drug Profile

Product Description

Mechanism Of Action

KI-1120 - Drug Profile

Product Description

Mechanism Of Action

KI-1128 - Drug Profile

Product Description

Mechanism Of Action

phenylephrine - Drug Profile

Product Description

Mechanism Of Action

prasterone - Drug Profile

Product Description

Mechanism Of Action

Prime Msk Shot - Drug Profile

Product Description

Mechanism Of Action

PrimePro - Drug Profile

Product Description

Mechanism Of Action

S1B-3006 - Drug Profile

Product Description

Mechanism Of Action

S1B-307 - Drug Profile

Product Description

Mechanism Of Action

sildenafil citrate - Drug Profile

Product Description

Mechanism Of Action

SIP-104 - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Target A3AR for Sexual Dysfunction - Drug Profile

Product Description

Mechanism Of Action

tadalafil - Drug Profile

Product Description

Mechanism Of Action

testosterone - Drug Profile

Product Description

Mechanism Of Action

testosterone - Drug Profile

Product Description

Mechanism Of Action

Female Sexual Dysfunction - Dormant Projects

Female Sexual Dysfunction - Discontinued Products

Female Sexual Dysfunction - Product Development Milestones

Featured News & Press Releases

Nov 04, 2022: Freya Pharma Solutions: ALETTA pivotal trial well received at ISSM/SMSNA Scientific Meeting

Nov 04, 2022: Freya Pharma Solutions: ALETTA pivotal trial well received at ISSM/SMSNA Scientific Meeting

Oct 17, 2022: Palatin announces publication of Vyleesi (bremelanotide) fMRI study in Women with Hypoactive Sexual Desire Disorder (HSDD)

Oct 10, 2022: Female sexual interest drug reaches tipping point with Phase III plans

Sep 28, 2022: Freya Pharma Solutions receives early EMA scientific advice on its upcoming phase 3 clinical trial to confirm efficacy of Lybrido in women suffering from FSIAD

Aug 29, 2022: Dar? Bioscience announces interim analysis of phase 2b RESPOND Study of Sildenafil Cream, 3.6% in women with female sexual arousal disorder

Jul 26, 2022: Palatin announces preliminary fourth quarter Vyleesi net product revenue increased 225% over prior quarter

Jun 29, 2022: Freya Pharma solutions announced its application for EMA scientific advice on its phase 3 clinical trial to confirm efficacy of lybrido in women suffering from FSIAD

Apr 12, 2022: Freya Pharma Solutions announces appointment of Dr. Jan van der Mooren as chief medical officer, to guide its pivotal phase 3 clinical trial with Lybrido against FSIAD

May 04, 2021: Palatin announces U.S. patent term extension for Vyleesi (bremelanotide injection)

Mar 24, 2021: Dar? Bioscience announces initiation of phase 2b RESPOND study of

sildenafil cream, 3.6% in women with female sexual arousal disorder

Aug 25, 2020: Knight and TherapeuticsMD announce Health Canada approval of IMVEXXY

Mar 09, 2020: Dare Bioscience presents positive Sildenafil Cream, 3.6% data supporting further development for the treatment of female sexual arousal disorder

Dec 11, 2019: Dar? Bioscience announces alignment with the FDA on phase 2b study design and novel primary endpoint PRO instruments to support the continued clinical development of Sildenafil Cream, 3.6%, a potential therapy for Female Sexual Arousal Disorder

Oct 30, 2019: Knight and TherapeuticsMD announce filing of new drug submission for Joyesta in Canada

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Female Sexual Dysfunction, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Female Sexual Dysfunction - Pipeline by Autotelic Bio Inc, 2022
Female Sexual Dysfunction - Pipeline by Callitas Therapeutics Inc, 2022
Female Sexual Dysfunction - Pipeline by Can-Fite BioPharma Ltd, 2022
Female Sexual Dysfunction - Pipeline by Dare Bioscience Inc, 2022
Female Sexual Dysfunction - Pipeline by Endoceutics Inc, 2022
Female Sexual Dysfunction - Pipeline by Freya Pharma Solutions BV, 2022
Female Sexual Dysfunction - Pipeline by Jupiter Wellness Inc, 2022
Female Sexual Dysfunction - Pipeline by Kuhnii Pharmaceutical Co Ltd, 2022
Female Sexual Dysfunction - Pipeline by Lennham Pharmaceuticals Inc, 2022
Female Sexual Dysfunction - Pipeline by Palatin Technologies Inc, 2022
Female Sexual Dysfunction - Pipeline by S1 Biopharma Inc, 2022
Female Sexual Dysfunction - Pipeline by TherapeuticsMD Inc, 2022
Female Sexual Dysfunction - Pipeline by Thomas Advanced Medical LLC, 2022
Female Sexual Dysfunction - Pipeline by Viramal Ltd, 2022
Female Sexual Dysfunction - Dormant Projects, 2022
Female Sexual Dysfunction - Dormant Projects, 2022 (Contd..1)
Female Sexual Dysfunction - Dormant Projects, 2022 (Contd..2)
Female Sexual Dysfunction - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Female Sexual Dysfunction, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Female Sexual Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/FCA5582DC3C2EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/FCA5582DC3C2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

